Similarly, additional studies have also reported reduced humoral responses in IBD patients treated with TNF inhibitors versus those treated with ustekinumab or vedolizumab [173,174,175], with one study noting more rapid decay in antibody titers in patients receiving TNF inhibitor therapy [173]. Here, TNF is linked to inflammatory bowel disease.